诊断学理论与实践

诊断学理论与实践 >

2019 , Vol. 18 >Issue 2: 121 - 126

DOI: https://doi.org/10.16150/j.1671-2870.2019.02.001

专家论坛

结核病的实验诊断技术应用及流程规范化

展开
  • 华中科技大学同济医学院附属同济医院检验科，湖北 武汉 430030

收稿日期: 2018-12-29

  网络出版日期: 2019-04-25

收起

本文引用格式

汪峰, 罗颖, 孙自镛 . 结核病的实验诊断技术应用及流程规范化[J]. 诊断学理论与实践, 2019 , 18(2) : 121 -126 . DOI: 10.16150/j.1671-2870.2019.02.001

参考文献

[1] Kaufmann SH, Parida SK. Tuberculosis in Africa: lear-ning from pathogenesis for biomarker identification[J]. Cell Host Microbe, 2008, 4(3):219-228.
[2] World Health Organization (WHO). Global tuberculosis report, 2014[R/OL]. WHO, 2014[2018-12-29].https://www.who.int/tb/en/.
[3] Minion J, Brunet L, Pai M. Fluorescent light emitting diode (LED) microscopy for the detection of Mycobacte-rium tuberculosis: a systematic review & meta-analysis[C/OL]. Geneva, Switzerland: WHO, 2009[2018-12-29].https://www.researchgate.net/publication/237765059_Fluores-cent_Light_Emitting_Diode_LED_Microscopy_for_the_Detection_of_Mycobacterium_tuberculosis_a_Systematic_Review_Meta-analysis
[4] Dorman S. Advances in the diagnosis of tuberculosis: current status and future prospects[J]. Int J Tuberc Lung Dis, 2015, 19(5):504-516.
[5] Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children[J]. Clin Infect Dis, 2017, 64(2):111-115.
[6] Henry D. Isenberg. Clinical Microbiology Procedures Handbook[M]. 4th. America Society for Microbiology, 2007.
[7] World Health Organization (WHO). Use of liquid TB culture and drug susceptibility testingDST in low and medium income settings: summary report of the expert group meeting on the use of liquid culture media[C]. WHO, 2007.
[8] Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases[J]. Am J Respir Crit Care Med, 2007, 175(4):367-416.
[9] World Health Organization(WHO). Implementing tuberculosis diagnostics: A policy framework[R/OL]. WHO, 2015[2018-12-29].https://www.who.int/tb/publications/implementing_TB_diagnostics/en/.
[10] World Health Organization(WHO). Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB)[C]. WHO, 2008.
[11] World Health Organization(WHO). Xpert MTB/RIF implementation manual Technical and operational ‘how-to’: practical considerations[R/OL]. WHO, 2014[2018-12-29].https://www.who.int/tb/publications/xpert_implem_manual/en/.
[12] World Health Organization (WHO). The use of loop-media-ted isothermal amplification (TB-LAMP) for the diagnosis of pulmonary tuberculosis: policy guidance[R/OL]. WHO, 2016[2018-12-29].https://www.who.int/tb/publications/lamp-diagnosis-molecular/en/.
[13] World Health Organization (WHO). Definitions and reporting framework for tuberculosis[C]. WHO, 2013.
[14] WS288-2017肺结核诊断[S]. 中华人民共和国卫生行业标准, 2017.
[15] World Health Organization( WHO). Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children[C]. WHO, 2013.
[16] World Health Organization ( WHO). XpertMTB/RIF:WHO Policy Update and Implementation Manual[C]. WHO, 2014.
[17] Dorman SE, Schumacher SG, Alland D, et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study[J]. Lancet Infect Dis, 2018, 18(1):76-84.
[18] Bahr NC, Nuwagira E, Evans EE, et al. Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous meningitis in HIV-infected adults: a prospective cohort study[J]. Lancet Infect Dis, 2018, 18(1):68-75.
[19] Lee YM, Kim SM, Park SJ, et al. Indeterminate T-SPOT.TB Test Results in Patients with Suspected Extrapulmonary Tuberculosis in Routine Clinical Practice[J]. Infect Chemother, 2013, 45(1):44-50.
[20] Latorre I, Carrascosa JM, Vilavella M, et al. Diagnosis of tuberculosis infection by interferon-gamma release assays in patients with psoriasis[J]. J Infect, 2014, 69(6):600-606.
[21] Lalvani A, Pareek M. Interferon gamma release assays: principles and practice[J]. Enferm Infecc Microbiol Clin, 2010, 28(4):245-252.
[22] Ling DI, Pai M, Davids V, et al. Are interferon-γ release assays useful for diagnosing active tuberculosis in a high-burden setting?[J]. Eur Respir J, 2011, 38(3):649-656.
[23] Wang F, Hou HY, Wu SJ, et al. Using the TBAg/PHA ratio in the T-SPOT(?).TB assay to distinguish TB disease from LTBI in an endemic area[J]. Int J Tuberc Lung Dis, 2016, 20(4):487-493.
[24] Bosco MJ, Hou H, Mao L, et al. The performance of the TBAg/PHA ratio in the diagnosis of active TB disease in immunocompromised patients[J]. Int J Infect Dis, 2017, 59:55-60.
[25] Zhou Y, Du J, Hou HY, et al. Application of ImmunoScore Model for the Differentiation between Active Tuberculosis and Latent Tuberculosis Infection as Well as Monitoring Anti-tuberculosis Therapy[J]. Front Cell Infect Microbiol, 2017, 7:457.
[26] Wang F, Hou H, Zhou H, et al. Use of TBAg/PHA ratio in distinguishing tuberculoma from cancer in solitary pulmonary nodule or mass[J]. Clin Respir J, 2018, 12(3):1174-1181.
[27] Wang F, Yu J, Zhou Y, et al. The Use of TB-Specific Antigen/Phytohemagglutinin Ratio for Diagnosis and Treatment Monitoring of Extrapulmonary Tuberculosis[J]. Front Immunol, 2018, 9:1047.
[28] Wu X, Huang H, Hou H, et al. Diagnostic Performance of a 5-Marker Predictive Model for Differential Diagnosis Between Intestinal Tuberculosis and Crohn's Disease[J]. Inflamm Bowel Dis, 2018, 24(11):2452-2460.
Options
文章导航

/

〈 〉